{
    "nct_id": "NCT04645797",
    "official_title": "A Phase 1 Dose Escalation Study to Evaluate Safety, Tolerability, and Pharmacokinetics/ Pharmacodynamics of APR003 in Patients With Advanced Colorectal Cancer (CRC) With Malignant Liver Lesions",
    "inclusion_criteria": "* ECOG performance status of 0 or 1\n* Must have disease that is considered non-surgically resectable.\n* Relapsed or persistent/refractory to at least two prior systemic treatment regimens for locally advanced or metastatic disease considered to be standard-of-care (SOC).\n* Must have previously received an irinotecan or oxaliplatin-based therapy, as well as a targeted antibody therapy for metastatic disease\n* Tumors that are MSI-H/dMMR must have previously received checkpoint inhibitor therapy\n* Adequate hepatic function\n* Adequate renal function\n* Normal coagulation panel\n* Willingness to use effective contraception\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 75 Years",
    "exclusion_criteria": "* Current or history of CNS metastases\n* Significant cardiovascular disease\n* Pregnant or breastfeeding",
    "miscellaneous_criteria": ""
}